The Food and Drug Administration (FDA) has approved Breo Ellipta (fluticasone furoate/vilanterol) for the once-daily treatment of asthma in patients aged 18 years and older. The approval of the ...
At first blush, the pedestrian world of drug manufacturing and the high-speed environs of Formula One racing would seem to have little in common. But GlaxoSmithKline ...
BREO is a fixed-dose combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2-agonist (LABA) vilanterol. Two strengths, 100/25mcg and 200/25mcg, have now been approved ...
BREO ELLIPTA (fluticasone furoate and vilanterol) Inhalation Powder Breo Ellipta (fluticasone furoate/vilanterol; GlaxoSmithKline and Theravance) has been made available for chronic obstructive ...
LONDON—A large clinical trial run by GlaxoSmithKline PLCGSK1.12%increase; green up pointing triangle has failed to show that the company’s Breo Ellipta inhaler extends life in patients with chronic ...
The Food and Drug Administration says it has approved a new once-a-day inhaler drug from GlaxoSmithKline for patients with chronic lung disease. The agency cleared the Breo Ellipta inhaler for ...
U.S approval of GlaxoSmithKline’s newest respiratory inhaler continues the global drugmaker’s shift from the blockbuster drug Advair to a suite of drugs that will be assembled at the British company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results